促通读药物的作用机制与临床应用

doi:10.16288/j.yczz.15-519

遗传 ›› 2016, Vol. 38 ›› Issue (7): 623-633.doi: 10.16288/j.yczz.15-519

促通读药物的作用机制与临床应用

付洋, 舒在悦, 顾鸣敏

上海交通大学医学院,上海 200025

收稿日期:2015-12-24 出版日期:2016-07-20 发布日期:2016-07-20
作者简介:付洋,2014级临床医学专业4+4学生,专业方向：临床医学。E-mail: fuyang19920114@sina.com
基金资助:
国家自然科学基金项目(编号：30470951,31071107,31571295)资助[Supported by the National Natural Science of China (Nos; 30470951,31071107,31571295)]

The functional mechanisms and clinical application of read-through drugs

Yang Fu, Zaiyue Shu, Mingmin Gu

School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China

Received:2015-12-24 Online:2016-07-20 Published:2016-07-20

摘要/Abstract

摘要： 据统计,全球有近1/10的遗传病由无义突变(Nonsense mutation)所致。无义突变通常导致翻译提前终止,生成截短的、无功能的蛋白质。近年来,促通读药物在无义突变所致遗传病的治疗方面取得了明显进展。然而,由于翻译终止的机制仍不甚明了,因此促通读药物的机制研究和临床应用面临着新的挑战。本文主要探讨了促通读药物治疗无义突变所致遗传病的作用机制,以及促通读药物在临床应用方面的研究进展、存在的问题及应对策略。

关键词: 遗传病, 无义突变, 促通读药物, 作用机制, 临床应用

Abstract: According to previous reports, nearly one in 10 genetic diseases are caused by nonsense mutations around the world. Nonsense mutations lead to premature transcription terminations in cells, which in turn generate non-functional, truncated proteins. In recent years, read-through drugs are playing increasing prominent roles in the researches related to genetic diseases caused by nonsense mutations. However, due to the fact that the mechanisms lying behind translation termination still remain to be elucidated, the mechanistic research and clinical application of read-through drugs are facing new challenges. This review mainly discusses about the pathogenesis of genetic diseases caused by nonsense mutations, and then introduces the current clinical application of read-through drugs. Finally, we display some problems that remain to be solved and propose some possible coping strategies.

Key words: genetic disease, nonsense mutation, read-through drug, functional mechanism, clinical application

付洋, 舒在悦, 顾鸣敏. 促通读药物的作用机制与临床应用[J]. 遗传, 2016, 38(7): 623-633.

Yang Fu, Zaiyue Shu, Mingmin Gu. The functional mechanisms and clinical application of read-through drugs[J]. HEREDITAS(Beijing), 2016, 38(7): 623-633.

参考文献

[1] Keeling KM, Bedwell DM. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA , 2011, 2(6): 837-852.
[2] Bidou L, Allamand V, Rousset JP, Namy O. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol Med , 2012, 18(11): 679-688.
[3] Lee HLR, Dougherty JP. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther , 2012, 136(2): 227-266.
[4] 乔中东. 分子生物学. 北京: 军事医学科学出版社, 2012.
[5] Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, Philippe M. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J , 1995, 14(16): 4065-4072.
[6] Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med , 1996, 2(4): 467-469.
[7] Fearon K, McClendon V, Bonetti B, Bedwell DM. Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem , 1994, 269(27): 17802-17808.
[8] Wohlgemuth I, Pohl C, Mittelstaet J, Konevega AL, Rodnina MV. Evolutionary optimization of speed and accuracy of decoding on the ribosome. Philos Trans R Soc Lond B Biol Sci , 2011, 366(1580): 2979-2986.
[9] Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol , 2012, 47(5): 444-463.
[10] Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V. Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell , 2002, 111(5): 721-732.
[11] Demeshkina N, Jenner L, Westhof E, Yusupov M, Yusupova G. A new understanding of the decoding principle on the ribosome. Nature , 2012, 484(7393): 256-259.
[12] Laurberg M, Asahara H, Korostelev A, Zhu JY, Trakhanov S, Noller HF. Structural basis for translation termination on the 70S ribosome. Nature , 2008, 454(7206): 852-857.
[13] Fan-Minogue H, Bedwell DM. Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA , 2008, 14(1): 148-157.
[14] Keeling KM, Brooks DA, Hopwood JJ, Li PN, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet , 2001, 10(3): 291-299.
[15] Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature , 2004, 432(7013): 112-118.
[16] Hoshino S, Imai M, Kobayashi T, Uchida N, Katada T. The eukaryotic polypeptide chain releasing factor (eRF3/ GSPT) carrying the translation termination signal to the 3'-Poly(A) tail of mRNA. Direct association of erf3/GSPT with polyadenylate-binding protein. J Biol Chem , 1999, 274(24): 16677-16680.
[17] Du M, Keeling KM, Fan LM, Liu XL, Kovacs T, Sorscher E, Bedwell DM. Clinical doses of amikacin provide more effective suppression of the human CFTR -G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med (Berl) , 2006, 84(7): 573-582.
[18] Howard MT, Anderson CB, Fass U, Khatri S, Gesteland RF, Atkins JF, Flanigan KM. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol , 2004, 55(3): 422-426.
[19] Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab , 2012, 105(1): 116-125.
[20] Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano- Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol , 2010, 67(6): 771-780.
[21] Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G, Lesure JF, Rousset JP, Edelman A. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med , 2007, 5: 5.
[22] Sangkuhl K, Schulz A, Römpler H, Yun J, Wess J, Schöneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo . Hum Mol Genet , 2004, 13(9): 893-903.
[23] Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem , 2010, 18(11): 3735-3746.
[24] Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, Baasov T, Bedwell DM. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl) , 2011, 89(11): 1149-1161.
[25] Gunn G, Dai YY, Du M, Belakhov V, Kandasamy J, Schoeb TR, Baasov T, Bedwell DM, Keeling KM. Long- term nonsense suppression therapy moderates MPS I-H disease progression. Mol Genet Metab , 2014, 111(3): 374-381.
[26] Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum Mol Genet , 2009, 18(20): 3906-3913.
[27] Allamand V, Bidou L, Arakawa M, Floquet C, Shiozuka M, Paturneau-Jouas M, Gartioux C, Butler-Browne GS, Mouly V, Rousset JP, Matsuda R, Ikeda D, Guicheney P. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin α2 chain mRNA in CMD myotubes. J Gene Med , 2008, 10(2): 217-224.
[28] Zilberberg A, Lahav L, Rosin-Arbesfeld R. Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons. Gut , 2010, 59(4): 496-507.
[29] Du M, Liu XL, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA , 2008, 105(6): 2064-2069.
[30] Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen GM, Jones S, Ren HY, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng HS, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature , 2007, 447(7140): 87-91.
[31] Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum Gene Ther , 2011, 22(5): 537-547.
[32] Wang BJ, Yang ZH, Brisson BK, Feng HS, Zhang ZQ, Welch EM, Peltz SW, Barton ER, Brown RH, Jr., Sweeney HL. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol (1985) , 2010, 109(3): 901-905.
[33] Du LT, Damoiseaux R, Nahas S, Gao K, Hu HL, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, Gatti RA. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med , 2009, 206(10): 2285- 2297.
[34] Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest , 1999, 104(4): 375-381.
[35] Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol , 2001, 49(6): 706-711.
[36] Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, Comi LI. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol , 2003, 22(1): 15-21.
[37] Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med , 2000, 161(3 Pt 1): 860-865.
[38] Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol , 2007, 37(1): 57-66.
[39] James PD, Raut S, Rivard GE, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood , 2005, 106(9): 3043-3048.
[40] Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen FQ, Schacht J, Pilch DS, Ben-Yosef T, Baasov T. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem , 2009, 52(9): 2836-2845.
[41] Haas M, Vlcek V, Balabanov P, Salmonson T, Bakchine S, Markey G, Weise M, Schlosser-Weber G, Brohmann H, Yerro CP, Mendizabal MR, Stoyanova-Beninska V, Hillege HL. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. Neuromuscul Disord , 2015, 25(1): 5-13.
[42] Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis , 2011, 34(2): 443-447.
[43] Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol , 2007, 47(4): 430-444.
[44] Finkel RS, Flanigan KM, Wong B, Bonnemann C, Sampson J, Sweeney HL, Reha A, Northcutt VJ, Elfring G, Barth J, Peltz SW. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One , 2013, 8(12): e81302.
[45] Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'Donnell M W, Peltz SW, McDonald CM, The PTC124-GD-007-DMD Study Group. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve , 2014, 50(4): 477-487.
[46] Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet , 2008, 372(9640): 719-727.
[47] Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, Donnelly K, Elfring GL, Ajayi T, Kerem E. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J , 2011, 38(1): 59-69.
[48] Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med , 2010, 182(10): 1262-1272.
[49] Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM, The Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med , 2014, 2(7): 539-547.
[50] Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA , 2009, 106(9): 3585-3590.
[51] Sheridan C. Doubts raised over 'read-through' Duchenne drug mechanism. Nat Biotechnol , 2013, 31(9): 771-773.
(责任编委: 赵彦艳)

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

促通读药物的作用机制与临床应用

The functional mechanisms and clinical application of read-through drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

[1]	牛煦然,尹树明,陈曦,邵婷婷,李大力. 基因编辑技术及其在疾病治疗中的研究进展[J]. 遗传, 2019, 41(7): 582-598.
[2]	周瑞,王以鑫,龙科任,蒋岸岸,金龙. LncRNA调控骨骼肌发育的分子机制及其在家养动物中的研究进展[J]. 遗传, 2018, 40(4): 292-304.
[3]	杨晓华, 张华峰, 赖江华. 中枢单胺类神经递质在酒精依赖中的分子作用机制[J]. 遗传, 2014, 36(1): 11-20.
[4]	夏天，肖丙秀，郭俊明. 长链非编码RNA的作用机制及其研究方法[J]. 遗传, 2013, 35(3): 269-280.
[5]	郭文婷，徐汪洋，顾鸣敏. 无义介导的mRNA降解机制及其在单基因遗传病中的作用[J]. 遗传, 2012, 34(8): 935-942.
[6]	李灏，姜颖，贺福初. 代谢组学技术及其在临床研究中的应用[J]. 遗传, 2008, 30(4): 389-399.
[7]	黄颖浩，杨琴波，邓云华，余念文，王擎，刘木根. 一个Ⅰ型神经纤维瘤家系的基因突变分析[J]. 遗传, 2008, 30(3): 309-312.
[8]	王帅，王栋，杜卫华，郝海生，朱化彬，王宗礼. 荷斯坦奶牛脊柱畸形综合征的研究进展[J]. 遗传, 2007, 29(9): 1049-1049―1054.
[9]	贺敏，李巍. 中国遗传咨询网——我国首个在线遗传咨询与遗传教育网站的开发[J]. 遗传, 2007, 29(3): 381-381―384.
[10]	傅祖明，陈可权，孙代平. 余姚市农村儿童遗传病的调查分析[J]. 遗传, 1994, 16(5): 23-25.
[11]	肖渝，张思霖，徐颖，潘晓放，胡应，张思仲. 14种多基因、疑为多基因遗传病的遗传率研究[J]. 遗传, 1994, 16(4): 9-13.